123 related articles for article (PubMed ID: 35964660)
21. [Effects of the aldose reductase inhibitor on diabetic polyneuropathy--the efficacy of F wave measurement].
Shimada H; Miki T; Kyogoku I; Kawagishi T; Inaba M; Okuno Y; Nishizawa Y; Morii H
No To Shinkei; 1998 Sep; 50(9):817-20. PubMed ID: 9789304
[TBL] [Abstract][Full Text] [Related]
22. I-123 MIBG cardiac imaging in diabetic neuropathy before and after epalrestat therapy.
Utsunomiya K; Narabayashi I; Nakatani Y; Tamura K; Onishi S
Clin Nucl Med; 1999 Jun; 24(6):418-20. PubMed ID: 10361937
[TBL] [Abstract][Full Text] [Related]
23. [Inhibition effect of epalrestat on rat lens osmotic expansion].
Ji LX; Shen N; Li CN; Liu Q; Huan Y; Shen ZF
Yao Xue Xue Bao; 2009 Oct; 44(10):1107-11. PubMed ID: 20055132
[TBL] [Abstract][Full Text] [Related]
24. Aldose reductase inhibition ameliorates pupillary light reflex and F-wave latency in patients with mild diabetic neuropathy.
Nakayama M; Nakamura J; Hamada Y; Chaya S; Mizubayashi R; Yasuda Y; Kamiya H; Koh N; Hotta N
Diabetes Care; 2001 Jun; 24(6):1093-8. PubMed ID: 11375376
[TBL] [Abstract][Full Text] [Related]
25. [Epalrestat].
Hotta N
Nihon Rinsho; 1997 Nov; 55 Suppl():204-11. PubMed ID: 9434468
[No Abstract] [Full Text] [Related]
26. A two-pronged photodynamic nanodrug to prevent metastasis of basal-like breast cancer.
Zhang J; Wang N; Li Q; Zhou Y; Luan Y
Chem Commun (Camb); 2021 Mar; 57(18):2305-2308. PubMed ID: 33533351
[TBL] [Abstract][Full Text] [Related]
27. Long-term effect of epalrestat on cardiac autonomic neuropathy in subjects with non-insulin dependent diabetes mellitus.
Ikeda T; Iwata K; Tanaka Y
Diabetes Res Clin Pract; 1999 Mar; 43(3):193-8. PubMed ID: 10369429
[TBL] [Abstract][Full Text] [Related]
28. Epalrestat improves diabetic wound healing via increased expression of nerve growth factor.
Nakagaki O; Miyoshi H; Sawada T; Atsumi T; Kondo T; Atsumi T
Exp Clin Endocrinol Diabetes; 2013 Feb; 121(2):84-9. PubMed ID: 23426701
[TBL] [Abstract][Full Text] [Related]
29. Ranirestat has a stronger inhibitory activity on aldose reductase and suppresses inflammatory reactions in high glucose-exposed endothelial cells.
Ishibashi Y; Matsui T; Matsumoto T; Kato H; Yamagishi S
Diab Vasc Dis Res; 2016 Jul; 13(4):312-5. PubMed ID: 27190083
[TBL] [Abstract][Full Text] [Related]
30. Inhibitor selectivity between aldo-keto reductase superfamily members AKR1B10 and AKR1B1: role of Trp112 (Trp111).
Zhang L; Zhang H; Zhao Y; Li Z; Chen S; Zhai J; Chen Y; Xie W; Wang Z; Li Q; Zheng X; Hu X
FEBS Lett; 2013 Nov; 587(22):3681-6. PubMed ID: 24100137
[TBL] [Abstract][Full Text] [Related]
31. Aldose reductase structures: implications for mechanism and inhibition.
El-Kabbani O; Ruiz F; Darmanin C; Chung RP
Cell Mol Life Sci; 2004 Apr; 61(7-8):750-62. PubMed ID: 15095000
[TBL] [Abstract][Full Text] [Related]
32. Epalrestat. A review of its pharmacology, and therapeutic potential in late-onset complications of diabetes mellitus.
Steele JW; Faulds D; Goa KL
Drugs Aging; 1993; 3(6):532-55. PubMed ID: 8312678
[TBL] [Abstract][Full Text] [Related]
33. Epalrestat, an Aldose Reductase Inhibitor, Restores Erectile Function in Streptozocin-induced Diabetic Rats.
Yang BB; Hong ZW; Zhang Z; Yu W; Song T; Zhu LL; Jiang HS; Chen GT; Chen Y; Dai YT
Int J Impot Res; 2019 Mar; 31(2):97-104. PubMed ID: 30214006
[TBL] [Abstract][Full Text] [Related]
34. Epalrestat, an Aldose Reductase Inhibitor Prevents Glucose-Induced Toxicity in Human Retinal Pigment Epithelial Cells In Vitro.
Senthilkumari S; Sharmila R; Chidambaranathan G; Vanniarajan A
J Ocul Pharmacol Ther; 2017; 33(1):34-41. PubMed ID: 27835059
[TBL] [Abstract][Full Text] [Related]
35. Effects of aldose reductase inhibitor on microneurographically assessed peripheral sympathetic nerve activity in rats.
Sato D; Kusunoki M; Shinzawa G; Feng Z; Nishina A; Nakamura T
Auton Neurosci; 2015 Dec; 193():69-73. PubMed ID: 26272532
[TBL] [Abstract][Full Text] [Related]
36. Effects of lignans extracted from Eucommia ulmoides and aldose reductase inhibitor epalrestat on hypertensive vascular remodeling.
Gu J; Wang JJ; Yan J; Cui CF; Wu WH; Li L; Wang ZS; Yu M; Gao N; Liu L; Ouyang DS
J Ethnopharmacol; 2011 Jan; 133(1):6-13. PubMed ID: 20817083
[TBL] [Abstract][Full Text] [Related]
37. Corticosteroids and aldose reductase inhibitor Epalrestat modulates cardiac action potential via KvĪ²1.1 (AKR6A8) subunit of voltage-gated potassium channel.
Tur J; Badole SL; Cheng F; Das A; Kukreja RC; Tipparaju SM
Mol Cell Biochem; 2017 Dec; 436(1-2):71-78. PubMed ID: 28585087
[TBL] [Abstract][Full Text] [Related]
38. Long-term effect of epalrestat, an aldose reductase inhibitor, on the development of incipient diabetic nephropathy in Type 2 diabetic patients.
Iso K; Tada H; Kuboki K; Inokuchi T
J Diabetes Complications; 2001; 15(5):241-4. PubMed ID: 11522497
[TBL] [Abstract][Full Text] [Related]
39. Aldo-keto reductase family 1 member B10 promotes cell survival by regulating lipid synthesis and eliminating carbonyls.
Wang C; Yan R; Luo D; Watabe K; Liao DF; Cao D
J Biol Chem; 2009 Sep; 284(39):26742-8. PubMed ID: 19643728
[TBL] [Abstract][Full Text] [Related]
40. Effectiveness of aldose reductase inhibitors for diabetic gastroenteropathy with constipation.
Nakamura T; Okano R; Uchiyama H; Seo Y; Okuda S
Intern Med; 1997 Jul; 36(7):479-83. PubMed ID: 9240496
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
